NHS England has decided to expand the use of stereotactic ablative radiotherapy (SABR) earlier than originally planned, making it available across England by the end of this financial year.
SABR is much more precise than conventional radiotherapy, meaning a higher dose of radiation can be applied without damaging healthy tissues. This in turn means patients need approximately five treatments, as opposed to over twenty with conventional radiotherapy.
NHS England said:
“By April every part of the country will be offering SABR treatment for non-small cell lung cancer and those with lung, lymph nodes and non-spine bone oligometastatic disease, in radiotherapy units nationwide. Further rollout for other disease types is planned for 2021/22.
Dr Nicholas van As, Chair of the UK SABR Consortium, said:
“The UK SABR Consortium is delighted to work with the NHS, enabling every radiotherapy service to deliver this innovative radiotherapy treatment. Our focus is on making sure patients have access to high quality treatment that meets their needs.”
Read more here.